By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Tibotec Pharmaceuticals Ltd 

Unit 4 Block 4B
Blanchardstown Corporate Park
Blanchardstown  Dublin  15  Ireland
Phone: 353-1-820-8114 Fax: 353-1-820-8082


SEARCH JOBS


Industry
Pharmaceutical






Company News
ChemDiv, Inc. Enters Into Research and Collaboration Agreement With Janssen Pharmaceutica N.V. and Tibotec Pharmaceuticals Ltd 12/20/2011 8:47:00 AM
Bristol-Myers Squibb Company (BMY) Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals Ltd for Phase II Combination Study in Patients Chronically Infected with Hepatitis C 12/2/2011 7:37:10 AM
Gilead Sciences, Inc. (GILD) Finalizes Agreement with Tibotec Pharmaceuticals Ltd to Develop and Commercialize a Single-Tablet Regimen of Prezista┬« with Emtriva┬«, GS 7340 and Cobicistat 11/16/2011 10:31:41 AM
Gilead Sciences, Inc. (GILD) and Johnson & Johnson (JNJ)'s Tibotec Pharmaceuticals Ltd to Create Combination HIV Therapy 11/16/2011 6:14:56 AM
Tibotec Pharmaceuticals Ltd to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at American Association for Study of Liver Diseases 11/7/2011 10:53:58 AM
Tibotec Pharmaceuticals Ltd's EDURANT(R) (rilpivirine) Receives Positive Opinion from CHMP for Use in Treatment-Naive Adults with HIV-1 9/23/2011 8:31:40 AM
Pharmasset, Inc. (VRUS) Enters into a Clinical Collaboration Agreement with Tibotec Pharmaceuticals Ltd for a Combination Study in Patients Chronically Infected with Hepatitis C 7/6/2011 8:15:14 AM
Tibotec Pharmaceuticals Ltd Signs Multiple Agreements With Generic Manufacturers, Including Mylan Inc. (MYL)'s Matrix Laboratories Limited (MAXL.BO), Aspen Pharmacare Holdings and Hetero Drugs to Provide Access to New HIV Treatment 1/27/2011 8:00:52 AM
Tibotec Pharmaceuticals Ltd Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. FDA 7/26/2010 10:48:27 AM
Tibotec Pharmaceuticals Ltd Announces TMC278 Pivotal Phase 3 Clinical Trials Achieve Primary Objective 7/22/2010 7:06:58 AM
123456
//-->